Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults

Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted into the Medicine Reimbursement System (GVS). 

Registration

Brexpiprazole (Rxulti®), an antipsychotic, is registered and indicated for the treatment of schizophrenia in adults.

Zorginstituut's advice

Based on the criteria for interchangeability, we conclude that brexpiprazole (Rzulti®) is interchangeable with the other drugs in GVS cluster N405AXAO V, which includes: aripiprazole, cariprazine, paliperidone, quetiapine and risperidone. A standard dose of 3 mg can be established.

This report is a summary of recommendations by Zorginstituut Nederland. The original text of this excerpt is in Dutch.